CritiTech and Finoso form US venture for API services
This article was originally published in Scrip
Executive Summary
The US drug development firm, CritiTech, and Finoso Pharma of India have formed an equally owned joint venture to provide active pharmaceutical ingredient (API)-related technology and other services to the pharmaceutical industry.